The Second Investor Conference of year 2022





2022Q3 YTD Consolidated Income Statement

Wellell

Unit: NTDK

	3Q22 YTD Review	3Q21 YTD Review	'22/'21 Var.(\$)	'22/'21 Var.(%)
Net Sales	1,967,093	1,755,722	211,371	12%
Gross Profit	801,103	743,767	57,336	8%
Gross Margin(%)	40.7%	42.4%	-1.6%	-4%
Operating Expenses	634,636	634,398	238	-
Income before Tax	182,114	129,244	52,870	41%
Net Income attributed to owner of the parent company	142,053	94,646	47,407	50%
Basic EPS(NT\$)	1.41	0.94	0.47	-

2022/09/30 Consolidated Balance Sheet(1)

Wellell

Unit: NTDK

	2022/09/30 Review	Variance		
	Amount	2021/09/30 Review Amount	Amount	%
Cash and cash equivalent	406,868	440,053	(33,185)	-8%
Current financial assets at fair value through profit or loss	92,762	114,251	(21,489)	-19%
Accounts receivable	472,100	366,738	105,362	29%
Other receivables	33,502	21,607	11,895	55%
Inventories	622,266	562,132	60,134	11%
Prepayments	38,035	43,812	(5,777)	-13%
Total current assets	1,685,325	1,571,775	113,550	7%
Amortized Cost Financial Assets	15,000	0	15,000	100%
Property, plant and equipment	718,175	741,692	(23,517)	-3%
Right-of-use asset	62,645	67,016	(4,371)	-7%
Intangible Assets	634,402	671,722	(37,320)	-6%
Total non-current assets	1,494,296	1,546,030	(51,734)	-3%
Total Assets	3,179,621	3,117,805	61,816	2%

2022/09/30 Consolidated Balance Sheet(2)


Wellell


Unit: NTDK

	2022/09/30 Review 2021/09/30 Review		Variano	Ce
	Amount	Amount	Amount	%
Short-term debt	398,237	290,112	108,125	37%
Accounts(including related parties)	161,751	222,827	(61,076)	-27%
Other payables and current liabilities	31,681	52,891	(21,210)	-40%
Long-term debt – current	9,312	8,924	388	4%
Total current liabilities	841,519	805,574	35,945	4%
Long-term debt	115,566	145,480	(29,914)	-21%
Defined benefit liability	5,478	7,670	(2,192)	-29%
Total long-term liabilities	193,417	232,625	(39,208)	-17%
Total liabilities	1,034,936	1,038,199	(3,263)	0%
Share capital	1,009,116	1,009,116	-	-
Additional paid-in capital	345,635	345,635	-	-
Total retained earnings	1,043,537	947,624	95,913	10%
Other equity	(259,726)	(227,966)	(31,760)	14%
Owners' equity attributed to the parent company	2,138,562	2,074,409	64,153	3%
Total owners' equity	2,144,685	2,079,606	65,079	3%
Total liabilities and owners' equity	3,179,621	3,117,805	61,816	2%

Sales by Product


Wellell






Sales by Department

Wellell







Operating Status Update

Optima Product wins Taipei Biotech Silver Awards Wellell

> 12th Aug. 2022 - Wellell Optima Series Product-wins Taipei Biotech Silver Awards.



SleepWell product wins 31thTaiwan Excellence Award Wellell

➤ 23th Nov. 2022- Wellell SleepWell - Cloud-based patient management system wins 31thTaiwan Excellence Award.





Year 2023 Business Focus





PAC(Pressure area care) to PRC(Patient Recovery Care)



Clinical Content




Digital Marketing

New project of Industry High Value Program

Wellell

➤ New Project "創新全時壓傷照護高階氣墊床系統開發" is approved by Industry Development Bureau, Ministry of Economic Affairs.



Thank you

